Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hamp Greene

Neurology Montgomery, AL Medical Doctor

NPI 1821104514 CMS profile 309190

2065 E South Blvd, Suite 201, Montgomery, AL 36116

Open in the dashboard

General payments

$10,496

707 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hamp Greene of Montgomery, AL is reported in the CMS Open Payments database as having received $10,496 across 707 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $311 26
2024 General $255 26
2023 General $402 37
2022 General $64 4
2021 General $3,206 204
2020 General $2,584 167
2019 General $3,674 243

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hamp Greene
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Hamp Greene were reported at $311. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Hamp Greene Neurology median Middle half National median
2019 $3,674 $474 $118–$2,177 $163
2020 $2,584 $367 $82–$2,309 $114
2021 $3,206 $438 $104–$2,547 $132
2022 $64 $442 $103–$2,388 $149
2023 $402 $464 $119–$2,312 $160
2024 $255 $468 $119–$2,323 $164
2025 $311 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $1,235 76 payments
  2. Amgen Inc. $1,169 68 payments
  3. Boston Scientific Corporation $947 89 payments
  4. Upsher-Smith Laboratories LLC $660 40 payments
  5. Novartis Pharmaceuticals Corporation $600 36 payments
  6. Biohaven Pharmaceuticals, Inc. $600 35 payments
  7. AbbVie, Inc. $547 49 payments
  8. UCB, Inc. $398 27 payments
  9. Teva Pharmaceuticals USA, Inc. $394 34 payments
  10. Biogen, Inc. $369 26 payments
  11. Other $3,577 227 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,293 695 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $201 11 payments
  3. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. AIMOVIG $1,461 84 payments
  2. BOTOX $981 52 payments
  3. NURTEC ODT $600 35 payments
  4. Infinion 16 $586 58 payments
  5. Tosymra Sumatriptan Nasal Spray $423 26 payments
  6. UBRELVY $384 38 payments
  7. TECFIDERA $369 26 payments
  8. TYSABRI $353 24 payments
  9. Zembrace SymTouch Sumatriptan Injection $318 19 payments
  10. QUDEXY XR Topiramate Extended Release Capsules $299 18 payments
  11. Other $5,919 409 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

707 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record